Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 318207, 8 pages
http://dx.doi.org/10.1155/2015/318207
Clinical Study

Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile

1Immunology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
2Gastroenterology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
3Gastroenterology Department, Virgen de las Nieves Hospital, 18014 Granada, Spain
4Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain
5Gastroenterology Department, Alcorcón Hospital, 28922 Madrid, Spain
6Gastroenterology Department, Fuenlabrada Hospital, 28942 Madrid, Spain
7Gastroenterology Department, Ramón y Cajal Hospital, 28034 Madrid, Spain
8Gastroenterology Department, La Paz Hospital, 28046 Madrid, Spain
9Gastroenterology Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa (IP), 28006 Madrid, Spain
10Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28002 Madrid, Spain
11Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla, 18100 Granada, Spain

Received 16 December 2014; Revised 11 March 2015; Accepted 11 March 2015

Academic Editor: Peter Szodoray

Copyright © 2015 Luz María Medrano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Abraham and J. H. Cho, “Inflammatory bowel disease,” The New England Journal of Medicine, vol. 361, no. 21, pp. 2066–2078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Franke, D. P. McGovern, J. C. Barrett et al., “Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci,” Nature Genetics, vol. 42, no. 12, pp. 1118–1125, 2010. View at Publisher · View at Google Scholar
  3. P. Rutgeerts, B. G. Feagan, G. R. Lichtenstein et al., “Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease,” Gastroenterology, vol. 126, no. 2, pp. 402–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. B. E. Sands, F. H. Anderson, C. N. Bernstein et al., “Infliximab maintenance therapy for fistulizing Crohn's disease,” The New England Journal of Medicine, vol. 350, no. 9, pp. 876–885, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. B. G. Feagan, M. Lémann, R. Befrits et al., “Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report,” Inflammatory Bowel Diseases, vol. 18, no. 1, pp. 152–160, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Cottone and V. Criscuoli, “Infliximab to treat Crohn's disease: an update,” Clinical and Experimental Gastroenterology, vol. 4, no. 1, pp. 227–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Arijs, R. Quintens, L. V. Lommel et al., “Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease,” Inflammatory Bowel Diseases, vol. 16, no. 12, pp. 2090–2098, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. J. M. Toonen, C. Gilissen, B. Franke et al., “Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis,” PLoS ONE, vol. 7, no. 3, Article ID e33199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. E. Lennard-Jones, “Classification of inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, Supplement, vol. 24, no. 170, pp. 2–6, 1989. View at Google Scholar · View at Scopus
  10. M. S. Silverberg, J. Satsangi, T. Ahmad et al., “Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology,” Canadian Journal of Gastroenterology, vol. 19, supplement, pp. 5A–36A, 2005. View at Google Scholar · View at Scopus
  11. R. F. Harvey and J. M. Bradshaw, “A simple index of Crohn's-disease activity,” The Lancet, vol. 1, no. 8167, p. 514, 1980. View at Google Scholar · View at Scopus
  12. J. F. Colombel, W. J. Sandborn, W. Reinisch et al., “Infliximab, azathioprine, or combination therapy for Crohn's disease,” The New England Journal of Medicine, vol. 362, no. 15, pp. 1383–1395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Gonzalez-Lama, A. Lopez-San Roman, I. Marin-Jimenez et al., “Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response,” Gastroenterology & Hepatology, vol. 31, no. 7, pp. 421–426, 2008. View at Google Scholar
  14. P. Miheller, P. L. Lakatos, G. Horváth et al., “Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe—a Hungarian nationwide observational study,” BMC Gastroenterology, vol. 9, article 66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Arijs, K. Li, G. Toedter et al., “Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis,” Gut, vol. 58, no. 12, pp. 1612–1619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Eggers, K. Sikora, M. Lorenz et al., “RAGE-dependent regulation of calcium-binding proteins S100A8 and S100A9 in human THP-1,” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 6, pp. 353–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Luley, F. Noack, H. Lehnert, and N. Homann, “Local calprotectin production in colorectal cancer and polyps-active neutrophil recruitment in carcinogenesis,” International Journal of Colorectal Disease, vol. 26, no. 5, pp. 603–607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. C. Manolakis, A. N. Kapsoritakis, E. K. Tiaka, and S. P. Potamianos, “Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease,” Digestive Diseases and Sciences, vol. 56, no. 6, pp. 1601–1611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. H. B. Hammer, M. K. Fagerhol, T. N. Wien, and T. K. Kvien, “The soluble biomarker calprotectin (a S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab,” Arthritis Research and Therapy, vol. 13, no. 5, article R178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Lood, M. Stenström, H. Tydén et al., “Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus,” Arthritis Research and Therapy, vol. 13, no. 2, article R60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Louis, J.-Y. Mary, G. Verniermassouille et al., “Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped,” Gastroenterology, vol. 142, no. 1, pp. 63.e5–70.e5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Molander, C.-G. Af Björkesten, H. Mustonen et al., “Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents,” Inflammatory Bowel Diseases, vol. 18, no. 11, pp. 2011–2017, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. K. R. Herrlinger, T. Witthoeft, A. Raedler et al., “Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease,” American Journal of Gastroenterology, vol. 101, no. 4, pp. 793–797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Nagyeri, M. Radacs, S. Ghassemi-Nejad et al., “TSG-6 protein, a negative regulator of inflammatory arthritis, forms a ternary complex with murine mast cell tryptases and heparin,” The Journal of Biological Chemistry, vol. 286, no. 26, pp. 23559–23569, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Offenberg, N. Brünner, F. Mansilla, F. Ørntoft Torben, and K. Birkenkamp-Demtroder, “TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles,” Molecular Oncology, vol. 2, no. 3, pp. 233–240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Koczan, R. Guthke, H.-J. Thiesen et al., “Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules,” European Journal of Dermatology, vol. 15, no. 4, pp. 251–257, 2005. View at Google Scholar · View at Scopus
  27. N. Nakamura, Y. Shimaoka, T. Tougan et al., “Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients,” DNA Research, vol. 13, no. 4, pp. 169–183, 2006. View at Publisher · View at Google Scholar · View at Scopus